Stacey E Brenner
Overview
Explore the profile of Stacey E Brenner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wender P, Baryza J, Brenner S, DeChristopher B, Loy B, Schrier A, et al.
Proc Natl Acad Sci U S A
. 2011 Mar;
108(17):6721-6.
PMID: 21415363
Modern methods for the identification of therapeutic leads include chemical or virtual screening of compound libraries. Nature's library represents a vast and diverse source of leads, often exhibiting exquisite biological...
2.
McGarraugh P, Brenner S
Tetrahedron
. 2010 Jan;
65(2):449-455.
PMID: 20066026
A new bifunctional organocatalyst with a novel structural and functional motif has been developed. This bifunctional sulfonamide organocatalyst was used in the conjugate addition of 1,3-dicarbonyl compounds (13) to β-nitrostyrenes...
3.
McGarraugh P, Brenner S
Org Lett
. 2009 Nov;
11(24):5654-7.
PMID: 19921792
While beta-ketoesters are useful Michael donors, they were previously ineffective in Michael-Michael cascade reactions using alpha,beta-unsaturated aldehydes in conjunction with diphenylprolinol silyl ether organocatalysts. However, through rational modification of substrates...
4.
Mitchell C, Brenner S, Garcia-Fortanet J, Ley S
Org Biomol Chem
. 2006 May;
4(10):2039-49.
PMID: 16688349
5-Pyrrolidin-2-yltetrazole is a versatile organocatalyst for the asymmetric conjugate addition of nitroalkanes to enones. Using this catalyst, this transformation requires short reaction times, tolerates a broad substrate scope, and possibly...
5.
Wender P, Baryza J, Brenner S, Clarke M, Craske M, Horan J, et al.
Curr Drug Discov Technol
. 2006 Feb;
1(1):1-11.
PMID: 16472215
Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile. Its natural and synthetic availability is severely limited. Function oriented synthesis provides a means to address...
6.
Mitchell C, Brenner S, Ley S
Chem Commun (Camb)
. 2005 Oct;
(42):5346-8.
PMID: 16244750
5-Pyrrolidin-2-yltetrazole performs as an improved catalyst for the asymmetric addition of a range of nitroalkanes to cyclic and acyclic enones, with good to excellent enantioselectivity.
7.
Stone J, Stang S, Zheng Y, Dower N, Brenner S, Baryza J, et al.
J Med Chem
. 2004 Dec;
47(26):6638-44.
PMID: 15588099
The functional properties of four diacylglycerol (DAG) analogues were compared using cell-signaling assays based on the protein RasGRP1, a DAG-regulated Ras activator. Compounds 1 and 2, synthetic analogues of bryostatin...
8.
Baryza J, Brenner S, Craske M, Meyer T, Wender P
Chem Biol
. 2004 Sep;
11(9):1261-7.
PMID: 15380186
Structurally simplified analogs of bryostatin 1, a marine natural product in clinical trials for the treatment of cancer, have been shown to be up to 50 times more potent than...
9.
Wender P, Baryza J, Bennett C, Bi F, Brenner S, Clarke M, et al.
J Am Chem Soc
. 2002 Nov;
124(46):13648-9.
PMID: 12431074
Macrocycle 1 is a new highly potent analogue of bryostatin 1, a promising anti-cancer agent currently in human clinical trials. In vitro, 1 displays picomolar affinity for PKC and exhibits...